MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- Indian - pharmaceuticals
- ASTRAZENECA PHARMA - DIVIS LABORATORIES
ASTRAZENECA PHARMA vs DIVIS LABORATORIES - Comparison Results
ASTRAZENECA PHARMA Change
AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More
DIVIS LABORATORIES 
Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More
Current Valuations
| ASTRAZENECA PHARMA | DIVIS LABORATORIES | ASTRAZENECA PHARMA/ DIVIS LABORATORIES |
|||
|---|---|---|---|---|---|
| P/E (TTM) | x | 113.7 | 48.1 | 236.3% | View Chart |
| P/BV | x | 34.8 | 12.9 | 270.5% | View Chart |
| Dividend Yield | % | 0.0 | 0.5 | - |
Financials
 ASTRAZENECA PHARMA  DIVIS LABORATORIES |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| ASTRAZENECA PHARMA Mar-18 |
DIVIS LABORATORIES Mar-19 |
ASTRAZENECA PHARMA/ DIVIS LABORATORIES |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 1,278 | 1,639 | 78.0% | |
| Low | Rs | 883 | 1,115 | 79.2% | |
| Sales per share (Unadj.) | Rs | 228.4 | 186.3 | 122.6% | |
| Earnings per share (Unadj.) | Rs | 10.4 | 51.0 | 20.3% | |
| Cash flow per share (Unadj.) | Rs | 16.3 | 57.3 | 28.4% | |
| Dividends per share (Unadj.) | Rs | 0 | 16.00 | 0.0% | |
| Dividend yield (eoy) | % | 0 | 1.2 | 0.0% | |
| Book value per share (Unadj.) | Rs | 98.8 | 261.8 | 37.7% | |
| Shares outstanding (eoy) | m | 25.00 | 265.47 | 9.4% | |
| Bonus/Rights/Conversions | - | - | - | ||
| Price / Sales ratio | x | 4.7 | 7.4 | 64.0% | |
| Avg P/E ratio | x | 104.2 | 27.0 | 385.7% | |
| P/CF ratio (eoy) | x | 66.4 | 24.0 | 276.5% | |
| Price / Book Value ratio | x | 10.9 | 5.3 | 207.9% | |
| Dividend payout | % | 0 | 31.4 | 0.0% | |
| Avg Mkt Cap | Rs m | 27,008 | 365,592 | 7.4% | |
| No. of employees | `000 | 1.4 | 11.8 | 11.4% | |
| Total wages/salary | Rs m | 1,535 | 5,423 | 28.3% | |
| Avg. sales/employee | Rs Th | 4,210.9 | 4,175.1 | 100.9% | |
| Avg. wages/employee | Rs Th | 1,132.2 | 457.7 | 247.4% | |
| Avg. net profit/employee | Rs Th | 191.1 | 1,141.8 | 16.7% | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 5,710 | 49,463 | 11.5% | |
| Other income | Rs m | 123 | 1,556 | 7.9% | |
| Total revenues | Rs m | 5,833 | 51,019 | 11.4% | |
| Gross profit | Rs m | 463 | 18,718 | 2.5% | |
| Depreciation | Rs m | 147 | 1,689 | 8.7% | |
| Interest | Rs m | 0 | 35 | 0.0% | |
| Profit before tax | Rs m | 438 | 18,551 | 2.4% | |
| Minority Interest | Rs m | 0 | 0 | - | |
| Prior Period Items | Rs m | 0 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
| Tax | Rs m | 179 | 5,023 | 3.6% | |
| Profit after tax | Rs m | 259 | 13,527 | 1.9% | |
| Gross profit margin | % | 8.1 | 37.8 | 21.4% | |
| Effective tax rate | % | 40.8 | 27.1 | 150.8% | |
| Net profit margin | % | 4.5 | 27.3 | 16.6% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 3,209 | 46,501 | 6.9% | |
| Current liabilities | Rs m | 2,070 | 8,468 | 24.4% | |
| Net working cap to sales | % | 20.0 | 76.9 | 26.0% | |
| Current ratio | x | 1.6 | 5.5 | 28.2% | |
| Inventory Days | Days | 72 | 131 | 55.3% | |
| Debtors Days | Days | 35 | 86 | 40.7% | |
| Net fixed assets | Rs m | 790 | 25,797 | 3.1% | |
| Share capital | Rs m | 50 | 531 | 9.4% | |
| "Free" reserves | Rs m | 2,419 | 68,962 | 3.5% | |
| Net worth | Rs m | 2,469 | 69,493 | 3.6% | |
| Long term debt | Rs m | 0 | 0 | - | |
| Total assets | Rs m | 4,605 | 80,383 | 5.7% | |
| Interest coverage | x | NM | 531.0 | - | |
| Debt to equity ratio | x | 0 | 0 | - | |
| Sales to assets ratio | x | 1.2 | 0.6 | 201.5% | |
| Return on assets | % | 5.6 | 16.9 | 33.3% | |
| Return on equity | % | 10.5 | 19.5 | 53.9% | |
| Return on capital | % | 17.7 | 26.7 | 66.3% | |
| Exports to sales | % | 0 | 0 | - | |
| Imports to sales | % | 0 | 24.6 | 0.0% | |
| Exports (fob) | Rs m | NA | NA | - | |
| Imports (cif) | Rs m | NA | 12,187 | 0.0% | |
| Fx inflow | Rs m | 300 | 41,238 | 0.7% | |
| Fx outflow | Rs m | 2,015 | 12,405 | 16.2% | |
| Net fx | Rs m | -1,715 | 28,833 | -5.9% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 88 | 9,543 | 0.9% | |
| From Investments | Rs m | -94 | -6,854 | 1.4% | |
| From Financial Activity | Rs m | NA | -2,459 | 0.0% | |
| Net Cashflow | Rs m | -6 | 230 | -2.5% | |
Share Holding
| Indian Promoters | % | 0.0 | 52.0 | - | |
| Foreign collaborators | % | 75.0 | 0.0 | - | |
| Indian inst/Mut Fund | % | 0.3 | 11.8 | 2.5% | |
| FIIs | % | 15.7 | 19.0 | 82.6% | |
| ADR/GDR | % | 0.0 | 0.0 | - | |
| Free float | % | 9.1 | 17.2 | 52.9% | |
| Shareholders | 12,856 | 31,796 | 40.4% | ||
| Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare ASTRAZENECA PHARMA With: PIRAMAL ENTERPRISES NOVARTIS PANACEA BIOTECH DR. REDDYS LAB GSK PHARMA
Compare ASTRAZENECA PHARMA With: MYLAN (US) ACTAVIS (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
Today's Market
Bloodbath on Dalal Street: 6 Reasons Why Sensex Nosedived 1,939 Points Today(Closing)
Indian share markets witnessed a sharp sell-off today and ended deep in the red.
Related Views on News
ASTRAZENECA PHARMA Announces Quarterly Results (3QFY21); Net Profit Down 21.2% (Quarterly Result Update)
Feb 11, 2021 | Updated on Feb 11, 2021For the quarter ended December 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 211 m (down 21.2% YoY). Sales on the other hand came in at Rs 2 bn (down 10.5% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.
DIVIS LABORATORIES Announces Quarterly Results (3QFY21); Net Profit Up 27.9% (Quarterly Result Update)
Feb 10, 2021 | Updated on Feb 10, 2021For the quarter ended December 2020, DIVIS LABORATORIES has posted a net profit of Rs 5 bn (up 27.9% YoY). Sales on the other hand came in at Rs 17 bn (up 19.1% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.
ASTRAZENECA PHARMA Announces Quarterly Results (1QFY21); Net Profit Down 13.4% (Quarterly Result Update)
Sep 22, 2020 | Updated on Sep 22, 2020For the quarter ended June 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 186 m (down 13.4% YoY). Sales on the other hand came in at Rs 2 bn (down 5.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.
DIVIS LABORATORIES Announces Quarterly Results (1QFY21); Net Profit Up 84.1% (Quarterly Result Update)
Aug 10, 2020 | Updated on Aug 10, 2020For the quarter ended June 2020, DIVIS LABORATORIES has posted a net profit of Rs 5 bn (up 84.1% YoY). Sales on the other hand came in at Rs 17 bn (up 50.0% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.
DIVIS LABORATORIES Announces Quarterly Results (4QFY20); Net Profit Up 35.4% (Quarterly Result Update)
Jun 8, 2020 | Updated on Jun 8, 2020For the quarter ended March 2020, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (up 35.4% YoY). Sales on the other hand came in at Rs 14 bn (up 9.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.
More Views on NewsMost Popular
It's the Beginning of a New Bull Phase in Smallcaps(Profit Hunter)
Feb 24, 2021Last time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.
Intraday Trading for a Living(Fast Profits Daily)
Feb 15, 2021In this video, I'll cover your queries on intraday trading and also share my view on how to decide stop losses and target prices.
Top 5 Stocks Mutual Funds Bought and Sold in January 2021(Sector Info)
Feb 16, 2021A look at what India's top equity mutual funds bought and sold in January 2021.
I Would Recommend this Small-cap Stock Over Tesla(Profit Hunter)
Feb 16, 2021Do you enjoy reading Tesla and Bitcoin stories? Here's a not so famous small-cap stock to profit from the rise of EVs.
MoreOUR TOP 5 IDEAS
- Access Now: Eight Steps to Your Eight Figure Fortune
- Are You Making One of These 15 Costly Mistakes While Investing. Learn more!
- Covid-19 Proof Multibagger Stocks - Download this FREE Report Now
- Free Report: The Secret to Increasing Your Trading Profits Daily!
- No Guessing, No Hunches, and No Missed Trends Ever! Join Us on YouTube Now.
ASTRAZENECA PHARMA SHARE PRICE
Feb 26, 2021 (Close)
TRACK ASTRAZENECA PHARMA
- Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON ASTRAZENECA PHARMA
ASTRAZENECA PHARMA 5-YR ANALYSIS
COMPARE ASTRAZENECA PHARMA WITH
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
- Basics of Value Investing
- Benjamin Graham
- How to Invest in Gold
- How to Invest in Silver
- Best Stocks to Buy Today
- Warren Buffett - The Value Investor
- The Best Small-cap Stocks to Buy
- The Best Bluechip Stocks to Buy
- Your Ultimate Guide to Penny Stock Investing
- 10 Rules for Successful Long-Term Investing
- How to Invest in the Share Market
- Momentum Moves
FOLLOW
APP
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.